Is a second course of intravenous immunoglobulin treatment in Guillain-Barré syndrome justifiable?

Is a second course of intravenous immunoglobulin treatment in Guillain-Barré syndrome justifiable?

•Responsiveness to a second course of IVIg treatment may be simply a coincidence.•IVIg may benefit the patient with regard to anti-infection treatment.•Complications or comorbidities should be considered before a second course of treatment.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical neuroscience 2020-07, Vol.77, p.251-252
Hauptverfasser: Yang, Jingyan, Jia, Rufu
Format: Artikel
Sprache:eng
Schlagworte:
Guillain-Barré syndrome
Intravenous immunoglobulin
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Responsiveness to a second course of IVIg treatment may be simply a coincidence.•IVIg may benefit the patient with regard to anti-infection treatment.•Complications or comorbidities should be considered before a second course of treatment.
ISSN:0967-5868
1532-2653
DOI:10.1016/j.jocn.2020.04.100